GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC

Panelists discuss how results from the GALAXY study reveal that circulating tumor DNA (ctDNA) status is a powerful predictor of outcomes and treatment benefit in patients with colorectal cancer (CRC), potentially revolutionizing personalized treatment approaches.

EP: 1.Colorectal Cancer: Rising Prevalence and the Promise of ctDNA

EP: 2.ctDNA in CRC Management: Evolving Approaches for Personalized Care

EP: 3.MRD Detection in CRC: Guiding Postsurgical Treatment Decisions and Monitoring

EP: 4.MRD Testing in CRC: Optimizing Chemo-Sparing Strategies and Residual Disease Control

EP: 5.DYNAMIC: ctDNA-Guided Therapy on Adjuvant Chemotherapy Decisions in Stage II Colon Cancer

EP: 6.ctDNA Insights From INTERCEPT, BESPOKE, COSMOS-CRC-01, and GALAXY Studies

EP: 7.GALAXY Study: ctDNA-Based MRD Monitoring in Resected CRC

Now Viewing

EP: 8.GALAXY Study Results: ctDNA Status Predicts Outcomes and Treatment Benefit in CRC

EP: 9.Treatment Strategies in ctDNA-Positive CRC

EP: 10.GALAXY 24-Month Data from ESMO 2024: MRD Status and ctDNA Clearance Key in CRC

EP: 11.CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and Prognosis

Recent Videos